Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Improved Performance of Neonatal Vascular Access Catheters via 3D Magnetic Printing

    SBC: N2 Biomedical, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Clinical treatment of infants in the neonatal intensive care unit NICU is particularly challenging due to their small anatomies medical instability and immature physiological processes Treatment is often complicated by the lack of therapeutic devices and instrumentation designed specifically to accommodate this unique patient population For instance curr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Identification of patients with diabetes at high risk for treatment failure

    SBC: LP INFORMATION TECHNOLOGY INC.            Topic: 200

    DESCRIPTION provided by applicant The overall goal of this project is to improve quality of care of patients with diabetes by identifying patients who may have particular difficulty reaching treatment targets and who could therefore potentially benefit from additional resources Investigators propose to achieve this goal by developing a technology to accurately identify patients at high risk f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Portable Multimode Persufflation/Perfusion System for Extended Hypothermic Kidney Preservation

    SBC: Giner, Inc.            Topic: NIDDK

    DESCRIPTION provided by applicant Portable Multimode Persufflation Perfusion System for Extended Hypothermic Kidney Preservation In over patients in the US started treatment for end stage renal disease ESRD These patients spend on average $ annually on treatment including dialysis In The U S the current waiting list for organ transplantation holds over patient ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. A novel drug detection assay using fluorescent biosensor technology

    SBC: GLSynthesis Inc.            Topic: 300

    DESCRIPTION provided by applicant This phase project has as its overall objectives to design engineer optimize and implement a novel genetically encoded fluorescent drug sensor FDS based on F rster Resonance Energy Transfer FRET by exploiting conformational rearrangements induced by drug interactions with human serum albumin SA SA is uniquely suited for a general drug sensor beca ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: 105

    DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...

    STTR Phase I 2015 Department of Health and Human Services
  6. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Multiple sclerosis MS is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults affecting over patients in the US and over million patients worldwide MS is a disease of high unmet medical need currently treatable with one of twelve FDA approved drugs all of which result in either significant i ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Phase IIB: Portable Device for Telecare Monitoring of Elderly People

    SBC: BioSensics LLC            Topic: NIA

    DESCRIPTION provided by applicant We propose to further develop field test and commercialize a reliable and robust sensor technology that allows the objective assessment of daily physical activity risk of falling frailty and activity organization among older adults in he home and community This is a Phase IIB STTR application During Phases Iandamp II BioSensics LLC in collaboration wit ...

    STTR Phase II 2015 Department of Health and Human Services
  9. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. GPCR antagonists as anti-Ebola virus entry inhibitors

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...

    STTR Phase I 2015 Department of Health and Human Services
US Flag An Official Website of the United States Government